Prosecution Insights
Last updated: November 20, 2026
Application No. 18/689,222

METHOD FOR PRODUCING COMPOUND

Final Rejection §102§103
Filed
Mar 05, 2024
Priority
Sep 07, 2021 — JP 2021-145084 +1 more
Examiner
CHANDRAKUMAR, NIZAL S
Art Unit
1625
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Mitsubishi Gas Chemical Company, Inc.
OA Round
2 (Final)
73%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
91%
With Interview

Examiner Intelligence

Grants 73% — above average
73%
Career Allowance Rate
1303 granted / 1794 resolved
+12.6% vs TC avg
Strong +18% interview lift
Without
With
+18.3%
Interview Lift
resolved cases with interview
Typical timeline
2y 3m
Avg Prosecution
91 currently pending
Career history
1900
Total Applications
across all art units

Statute-Specific Performance

§101
2.2%
-37.8% vs TC avg
§103
29.1%
-10.9% vs TC avg
§102
11.0%
-29.0% vs TC avg
§112
36.8%
-3.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1794 resolved cases

Office Action

§102 §103
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Amended claims 1, 4-20 are pending. Claim Rejections - 35 USC § 103 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claim(s) 1, 4-20 is/are rejected under 35 U.S.C. 103 as obvious over Sheng JACS Au (2021), 1(4), 501-507 (April 7 2021) in view of Lancien, Chem.Cat. Chem (2021), 13(1), 247-259 and Yu, CN108484426. Applicant Remarks are not persuasive. Applicants arguments focus on amendments to claims and further that the presence of carboxyl group affects the reaction behavior of the formyl containing substrate. The rejection is not under Claim Rejections - 35 USC § 102. As such that Sheng does not disclose the starting material containing formyl, carboxyl and furan-ring is irrelevant. First of all, as pointed out in the previous action, Sheng does teach furan and formyl group containing compounds in Scheme 1. That the presence of carboxyl group would not affect the well-known reductive amination reaction is evidenced by the teachings of Yu (see previous action page 2). As per the teachings of Yu, Yu teaches at page 1/3 teach PNG media_image1.png 112 472 media_image1.png Greyscale X = aromatic, Phenylene ‘ammonium salt’ As seen above, the difference is in the aromatic ring. The instant case differs from Yu chemistry in that the aromatic ring Yu is replaced with hetero atom containing aromatic ring in the instant claims. The presence of base PNG media_image2.png 22 36 media_image2.png Greyscale and acid PNG media_image3.png 22 46 media_image3.png Greyscale together is anticipated to make PNG media_image4.png 14 96 media_image4.png Greyscale by acid-base reaction! The presence of alkylamine (see instant claims 14, 15) is akin to use of excess ammonia in Yu process, because the amines of 14 and 15 are expected to have the same effect as that of Yu’s ammonia (forming salt with carboxylic acid). Applicant is also encouraged to place on record how the amines of claims 14 and 15 do not participate in the reductive amination reaction. In this context the statement PNG media_image5.png 80 718 media_image5.png Greyscale does no more than admits that the instant claimed process produces large amount of byproducts. The invention is a selective combination of the inventions by the prior arts done in a manner obvious to one of ordinary skill in the art. Patent for the combination of known elements wherein their functions remain the same withdraws “what is already known into field of its monopoly and diminishes resources available to skilled men”. Sakraida v. Ag Pro, Inc.189 USPQ 449, 425 US 273, (1976). Obviousness can be established by combining or modifying the teachings of the prior art to produce the claimed invention where there is some teaching, suggestion, or motivation to do so found either in the references themselves or in the knowledge generally available to one of ordinary skill in the art. Accordingly, the claims do not recite an unobvious distinction over the prior art. Further, a reference is relevant not only for what it expressly teaches, but also for what it would have conveyed to one of ordinary skill in the art. See In re Opprecht, 12 USPQ2d 1235, 1236 (Fed. Cir. 1989); In re Bode, 193 USPQ 12 (CCPA 1976). In light of the foregoing discussion, the Examiner finds that the claimed subject matter as a whole would have been obvious to one of ordinary skill in the art at the time the invention was made, in view of the cited references and the knowledge generally available in the art. Accordingly, the claims are rejected under 35 U.S.C. § 103. Suggestion: Amend claims to include all the details (starting materials, solvent, reagent, catalyst, temperature, pressure etc.) of chemistry at page 17, in Example 1. Following is from previous action: Sheng teaches Calcium Phosphide for Reductive Amination of Carbonyl Compounds. At page 504 and 505 Schemes 1-3 in Sheng provides multiple examples of the fantastic chemistry which includes the Reaction Conditions (process parameters). The Reaction Conditions of Sheng include the possibilities of the limitations (process parameters such as solvent) of the instant claims 1-3, 5-20. The difference is the presence of PNG media_image6.png 14 44 media_image6.png Greyscale (as in the instant formulae). More specifically, Sheng teaches that the X of the instant formulae with a variety of substituents, present in the starting material (and in the product) are unaffected by the Reaction Conditions of solvent, temperature (as limited by the instant dependent claims). The Examples include the instant furan as in claim 4, see Scheme 1 three furan compounds. Thus the substituents on X of the formulae play a spectator role with respect to Calcium Phosphide and the said Reaction Conditions. Sheng is silent with respect to PNG media_image6.png 14 44 media_image6.png Greyscale as substituent. At page 503, column B, Sheng teaches that ‘.various functional groups, such as halogen, methoxy, amide, and boronic ester moieties, were tolerant under these reaction conditions, providing the corresponding primary amines in excellent yields’. Since substituent do not participate in the desired reaction, as exemplified by Sheng, one of skill in the art would have reasonable expectation of success in arriving at the limitations of instant claim 4, by starting with known starting material Formula (1-1) to make known product (2-1) using the chemistry of Sheng. For motivation see Lancien. According to Lancien, making the valuable 2-1 is a challenge, see page 248, column A second full paragraph. Accordingly, the claims do not recite an unobvious distinction over the prior art. Further, a reference is relevant not only for what it expressly teaches, but also for what it would have conveyed to one of ordinary skill in the art. See In re Opprecht, 12 USPQ2d 1235, 1236 (Fed. Cir. 1989); In re Bode, 193 USPQ 12 (CCPA 1976). In light of the foregoing discussion, the Examiner finds that the claimed subject matter as a whole would have been obvious to one of ordinary skill in the art at the time the invention was made, in view of the cited references and the knowledge generally available in the art. Accordingly, the claims are rejected under 35 U.S.C. § 103. Prior art made of record and not relied upon is considered pertinent to applicant's disclosure. Afanasyev, Reductive Amination in the Synthesis of Pharmaceuticals, Chem.Rev.2019,119,11857−11911. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to NIZAL S CHANDRAKUMAR whose telephone number is (571)272-6202. The examiner can normally be reached M-F 8-5 EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Andrew Kosar can be reached at (571) 272-0913. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /NIZAL S CHANDRAKUMAR/Primary Examiner, Art Unit 1625
Read full office action

Prosecution Timeline

Mar 05, 2024
Application Filed
Jul 01, 2026
Non-Final Rejection mailed — §102, §103
Sep 29, 2026
Response Filed
Nov 10, 2026
Final Rejection mailed — §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12774276
MALT1 Modulators and Uses Thereof
2y 1m to grant Granted Oct 27, 2026
Patent 12767668
IMIDAZOTHIAZOLE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF
3y 5m to grant Granted Oct 20, 2026
Patent 12767644
USE OF 3-ARYLPHTHALIDES AND DERIVATIVES THEREOF AS ANTI-INFLAMMATORY AGENTS
2y 8m to grant Granted Oct 20, 2026
Patent 12758562
SYNTHESIS AND PROCESSING OF POLY(PRO-DRUG) MATERIALS FOR EXTENDED DRUG RELEASE AND USES THEREOF
4y 11m to grant Granted Oct 13, 2026
Patent 12753175
PROCESS FOR THE PREPARATION OF (9S)-2-BROMO-9-(2,3,4-TRIFLUOROPHENYL)-6,7,8,9-TETRAHYDRO-5H-[1,2,4]TRIAZOLO[1,5-A]AZEPINE
4y 4m to grant Granted Oct 06, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
73%
Grant Probability
91%
With Interview (+18.3%)
2y 3m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1794 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month